Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones01-07

DJ Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. $(CRBP)$ rose 2.81% to $8.05 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.65% to 23,547.17 and the Dow Jones Industrial Average rising 0.99% to 49,462.08.

The stock's rise snapped a two-day losing streak.

Corbus Pharmaceuticals Holdings Inc. closed 60.85% short of its 52-week high of $20.56, which the company achieved on October 20th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. $(VNDA)$ rose 3.30% to $8.13, Fortress Biotech Inc. (FBIO) fell 1.41% to $4.21, and Viking Therapeutics Inc. (VKTX) rose 0.50% to $32.30.

Trading volume (146,256) remained 313,365 below its 50-day average volume of 459,621.

Data source: Dow Jones Market Data, FactSet. Data compiled January 6, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

January 06, 2026 17:20 ET (22:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment